Davos 2016 – What If: You Are Still Alive in 2100?

Join an in-depth discussion that explores the possible, plausible and probable impacts of significantly extended lifespans.

From reversing the effects of ageing on the brain and editing genetic diseases to artificial intelligence and downloading thoughts and memories, scientists are pushing the boundaries of the human lifespan. What would be the impact on life, love and work if you could live to 150 (or forever)?

Elizabeth Blackburn, Professor, University of California, San Francisco, USA.
Thomas DeRosa, Chief Executive Officer, Welltower, USA.
Lynda Gratton, Professor of Management Practice, London Business School, United Kingdom.
Derek Yach, Chief Health Officer, Vitality, USA.

Moderated by Nancy Gibbs, Managing Editor, Time Magazine, USA.

Human Enhancement and the Law conference on 7/8th January 2016 (Oxford, UK)

The increasing production and use of what can broadly be categorised as ‘human enhancement technologies’ is creating challenges for existing legal frameworks.

This conference and resulting special edition of the Journal of Law, Information and Science, will aim to identify the legal issues that arise as a result of these developments in human enhancement technologies.

During this conference, Didier Coeurnelle, member of the board of the ILA, will speak about “The Right to (Radical) Life Extension Considered a Human Right”

Marcelo de Araujo will apporach “The ethics of editing the human genome with CRISPR-Cas9”

More information about the conference: https://www.law.ox.ac.uk/research-and-subject-groups/neurolaw-project/human-enhancement-and-law-regulating-future

Program of the conference: https://www.law.ox.ac.uk/sites/files/oxlaw/field/field_document/schedule_-_preliminary_draft.pdf

ILA Press release: Metformin, Zuckerberg and British citizens on the road to longevity

On December 2nd, the US Food and Drug Administration authorized a five-year test of Metformin on 3,000 people aged 60 and older. Metformin already allows a dramatic lengthening of life for diabetic patients. The objective of this revolutionary research is to check whether aging in “ordinary” elderly citizens is slowed down with this product (like it is in mice). In other words, the goal is to treat aging as a disease.

The day before, on December 1st, Mark Zuckerberg, celebrating the birth of his daughter, decided to devote most of his fortune, or 43 billion dollars to create (with his wife) a non-profit company. One of the objectives of the company will be to fight against the diseases that remain today. In a letter to his daughter and his few (million) Facebook friends, he writes: “Today we spend about 50 times more as a society treating people who are sick than we invest in research so you won’t get sick in the first place. (…) Can our generation cure disease so you live much longer and healthier lives? ” Continue reading “ILA Press release: Metformin, Zuckerberg and British citizens on the road to longevity”

Mark Zuckerberg: A letter to our daughter

Dear Max,

Your mother and I don’t yet have the words to describe the hope you give us for the future. Your new life is full of promise, and we hope you will be happy and healthy so you can explore it fully. You’ve already given us a reason to reflect on the world we hope you live in.

Like all parents, we want you to grow up in a world better than ours today.

While headlines often focus on what’s wrong, in many ways the world is getting better. Health is improving. Poverty is shrinking. Knowledge is growing. People are connecting. Technological progress in every field means your life should be dramatically better than ours today. Continue reading “Mark Zuckerberg: A letter to our daughter”

World’s first anti-ageing drug could see humans live to 120

Scientists believe the common diabetes drug metformin could hold the secret of long life and want to start a groundbreaking human trial in 2016.

The world’s first anti-ageing drug will be tested on humans next year in trials which could see diseases like Alzheimer’s and Parkinson’s consigned to distant memory.

Scientists now believe that it is possible to actually stop people growing old as quickly and help them live in good health well into their 110s and 120s. Continue reading “World’s first anti-ageing drug could see humans live to 120”

ILA position with respect to WHO’s Global Strategy and Action Plan on Ageing and Health

The World Health Organization launched public consultations on the Global Strategy and Action Plan on Ageing and Health, which will continue until October 30, 2015, and invited NGOs to take part.

Zero draft of the Strategy
English Version
French Version

The Longevity community should take part in these consultations, as this document will have a significant influence on the national policies and resources allocated for research on aging and longevity. Continue reading “ILA position with respect to WHO’s Global Strategy and Action Plan on Ageing and Health”

ILA celebrates the Day of Older Persons by series of events to support longevity technologies

It has become a tradition to intensify the dialogue about longevity technologies development in September and October, before and after the UN International Day of Older Persons. This year, the ILA representatives organized and visited the events in several countries. Continue reading “ILA celebrates the Day of Older Persons by series of events to support longevity technologies”

Slowing down ageing

What is ageing and how do we prevent it? A nice, easy to understand, non-technical introduction about how genetic research can be applied to increase healthy longevity.

João Pedro de Magalhães is a researcher at the University of Liverpool studying aging, longevity and genome biology. His research focuses on understanding the genetic, cellular, and molecular mechanisms of ageing.

Halting Old-Age Multimorbidity in Europe (HOME)

Project Proposal

Halting Old-Age Multimorbidity in Europe (HOME) by addressing old-age multimorbidity as a diagnosable and treatable medical condition

HOME project – Halting Old-age Multimorbidity in Europe – ISRLA

Executive summary
Rationale
Methodological challenges to be solved
Project aims
Methodologies to be applied
HOME’s 3-year project plan
Team (tentative)
Selected sources

Potential scientific participants and supporters are sought! Continue reading “Halting Old-Age Multimorbidity in Europe (HOME)”

Comorbidity Detection

CD Technologies – Comorbidity Detection Technologies (CDT) – is a dynamic multidisciplinary company dedicated to mathematical diagnostic modeling of aging and aging-related diseases, for the purposes of their early preventative and personalized therapy.

CDT develops the practically applicable and at the same time sophisticated expert software system for indication of physiological age, for early diagnosis of aging-related ill health and personalization of aging-related and healthspan extending treatments – “The Quantified Longevity Guide – QLG”. The system will facilitate early detection and corresponding preventive early treatment of major aging-related diseases (such as cancer, Alzheimer’s disease, heart disease and diabetes), based on the assessment of physiological age. Continue reading “Comorbidity Detection”